橙子视频app安卓下载,91橙子视频,橙子视频旧款,橙子视频在线官网

siRNA to inhibit KAAG1 expression using RNA interference.

This product is provided as two 5 nmol vials (10 nmol), three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. The siRNA oligos are also chemically modified (2'-OMe) for increased stability and enhanced knockdown in vitro and in vivo.

Target	KAAG1
Reactivity	Human
Host	Synthetic
Tested Applications	RNAi
Purity	> 97%
Form	Lyophilized
Specificity	KAAG1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Storage	Shipped at 4 °C. Store at -20 °C for up to one year.
Swiss Prot	Q9UBP8
GeneID	353219
Gene Symbol	KAAG1
Directions for use	1. Transfect with 100 nM siRNA 48 to 72 hours prior to cell lysis. 2. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. 3. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. Each vial is suitable for 250 transfections in a 24 well plate (20 pmol for each well).
Quality Control	Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.